A screen displays the logo fro Cigna Corp. on the floor at the New York Stock Exchange (NYSE) in New York, U.S., July 16, 2019. REUTERS/Brendan McDermid
(Reuters) – Health insurer Cigna Corp on Thursday announced a new program that covers costs for expensive gene therapies that will cut out-of-pocket payments for customers.
Spark Therapeutics Inc and Novartis AG’s blindness therapy, Luxturna, and Novartis’ $2.1 million spinal muscular atrophy treatment, Zolgensma, will be the first two gene therapies included in the program, the company said.
Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva
Our Standards:The Thomson Reuters Trust Principles.
Credit: Source link
Discussion about this post